SEARCH

SEARCH BY CITATION

Reference

  • 1
    Rush AJ, Trivedi MH, Ibrahim HM et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573583.
  • 2
    Zung WW. A self-rating depression scale. Arch Gen Psychiatry 1965;12:6370.
  • 3
    Beck AT, Ward CH, Mendelson M, Mock JE, Erbaugh JK. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561571.
  • 4
    Shelton RC. Treatment options for refractory depression. J Clin Psychiatry 1999;60(suppl. 4):5761.
  • 5
    Miller IW, Keitner GI, Schatzberg AF et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998;59:608619.
  • 6
    Frank E, Prien RF, Jarrett RB et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.. Arch Gen Psychiatry 1991;48:851855.
  • 7
    Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:5662.
  • 8
    Fava M, Rush AJ, Trivedi MH et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 2003;26:457494.
  • 9
    Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:2840.
  • 10
    Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:19051917.
  • 11
    Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263287.
  • 12
    Weisstaub NV, Zhou M, Lira A et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 2006;313:536540.
  • 13
    Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005;66(suppl. 8):3040.
  • 14
    Bymaster FP, HemrickLuecke SK, Perry KW, Fuller RW. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha(1)-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 1996;124:8794.
  • 15
    Bymaster FP, Calligaro DO, Falcone JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:8796.
  • 16
    Tarazi FI, Baldessarini RJ, Kula NS, Zhang K. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2003;306:11451151.
  • 17
    Meltzer HY, Bastani B, Ramirez L, Matsubara S. Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatry Neurol Sci 1989;238:332339.
  • 18
    Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Biol Psychiatry 2003;27:11591172.
  • 19
    Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O’Laughlin IA, Meltzer HY. 5-HT (2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001;76:15211531. (Abstract).
  • 20
    Liegeois JF, Ichikawa J, Meltzer HY. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 2002;30:947.
  • 21
    Gobert A, Rivet JM, Lejeune F et al. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 2000;36:205221.
  • 22
    Ichikawa J, Meltzer HY. R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther 1999;291:12271232.
  • 23
    Di Mascio M, Esposito E. The degree of inhibition of dopaminergic neurons in the ventral tegmental area induced by selective serotonin reuptake inhibitors is a function of the density-power-spectrum of the interspike interval. Neuroscience 1997;79:957961.
  • 24
    Di Mascio M, Di Giovanni G, Di Matteo V, Prisco S, Esposito E. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Brain Res Bull 1998;46:547554.
  • 25
    Tollefson GD, Sanger TM. Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? Schizophr Res 1999;35(suppl.):S13S21.
  • 26
    Shelton RC, Tollefson GD, Tohen M et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131134.
  • 27
    Shelton RC, Williamson D, Corya SA et al. Olanzapine/fluoxetine combination for treatment resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005;66:12891297.
  • 28
    Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006;23:364372.
  • 29
    Thase ME, Corya SA, Osuntokun O et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007;68:224236.
  • 30
    Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999;60:256259.
  • 31
    Rapaport MH, Gharabawi GM, Canuso CM et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006;31:25052513.
  • 32
    Gharabawi G, Canuso C, Pandina G et al. A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder. Int J Neuropsychopharmacol 2006;9(suppl. 1):S236.
  • 33
    Keitner GI, Garlow SJ, Ryan CE et al. Risperidone augmentation for patients with difficult-to-treat major depression. 159th Annual Meeting of the American Psychiatric Association. Toronto, Canada: American Psychiatric Association, 2006.
  • 34
    Calabrese JR, Keck PE, Jr. Macfadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:13511360. (Generic)
  • 35
    Mattingly GW, Ilivicky HJ, Canale JP, Anderson RH. Quetiapine augmentation for treatment-resistant depression. 159th Annual Meeting of the American Psychiatric Association. Toronto, Canada: American Psychiatric Association, 2006.
  • 36
    McIntyre A, Gendron A, McIntyre A. Quetiapine reduces residual depressive and prominent anxiety symptoms in partial responders to selective serotonin reuptake inhibitors (SSRIs) serotonin norepinephrine reuptake inhibitors (SNRIs) with major depression: an 8-week, double-blind, randomised, placebo-study. Toronto, Ont., Canada: American Psychiatric Association, Annual Meeting, 2006. (Generic)
  • 37
    Khullar A, Chokka P., Fullerton D, McKenna S, Blackman A. Toronto, Canada: 159th Annual Meeting of the American Psychiatric Association, 2006. (Generic)
  • 38
    Schmidt AW, Lebel LA, Howard HR, Jr. Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001;425:197201. (Generic)
  • 39
    Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O’Laughlin IA, Meltzer HY. 5-HT(2A)andD(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001;76:15211531.
  • 40
    Papakostas GI, Petersen TJ, Nierenberg AA et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004;65:217221.
  • 41
    Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007;68:10711077.
  • 42
    Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry 2004;16:189194. (Abstract)
  • 43
    Hellerstein DJ. Aripiprazole as an adjunctive treatment for refractory major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:13471348.
  • 44
    Papakostas GI, Petersen TJ, Kinrys G et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005;66:13261330.
  • 45
    Worthington JJ, III. Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005;20:911.
  • 46
    Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005;66:12161220.
  • 47
    Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 2004;65:975981.
  • 48
    Keck PE, Jr. McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000;61(suppl. 4):3338.
  • 49
    Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;1964:22912314.
  • 50
    Tollefson GD, Kuntz AJ. Review of recent clinical studies with olanzapine. Br J Psychiatry Suppl 1999;37:3035.
  • 51
    Goff DC, Posever T, Herz L et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18:296304.